The leaders of this year’s list of the most anticipated drug launches will likely come as no surprise: Fierce’s annual report on the biggest potential launches of 2026 details how the next obesity meds from Novo Nordisk and Eli Lilly are expected to rake in a respective $17.2 billion and $11.8 billion in annual sales by 2032, so long as they score their expected approvals this year.

Elsewhere in the report are candidates from the likes of Gilead Sciences, Johnson & Johnson, AstraZeneca and other biopharmas big and small, spanning a range of indications from breast cancer to essential tremor. All together, predicted 2032 sales for the year’s top 10 weigh in at nearly $46 billion.

In this week’s episode of “The Top Line,” Fierce’s Andrea Park and Gabrielle Masson dive into the report, mapping out how it stacks up against last year’s edition and digging into the enormous sales potential of the top two drugs on the list. 

To learn more about the topics in this episode: 

• Top 10 most anticipated drug launches of 2026

• Novo Nordisk stock crashes after CagriSema misses phase 3 weight-loss goal

• Lilly's obesity pill largely maintains weight lost on injectable GLP-1s

• Top 10 most anticipated drug launches of 2025 

See omnystudio.com/listener for privacy information.